488 related articles for article (PubMed ID: 20072836)
1. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
2. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
3. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
5. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
6. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Fenaux P
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
[TBL] [Abstract][Full Text] [Related]
8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
9. Decitabine in myelodysplastic syndromes.
Saba HI; Wijermans PW
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
11. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
12. Decitabine and its role in the treatment of hematopoietic malignancies.
Plimack ER; Kantarjian HM; Issa JP
Leuk Lymphoma; 2007 Aug; 48(8):1472-81. PubMed ID: 17701577
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
14. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
15. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
16. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
19. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
20. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
